Lipocine Inc. (NASDAQ:LPCN) Short Interest Update

Lipocine Inc. (NASDAQ:LPCN) was the target of a large growth in short interest in December. As of December 31st, there was short interest totaling 157,602 shares, a growth of 41.9% from the December 15th total of 111,083 shares. Approximately 3.0% of the company’s stock are short sold. Based on an average trading volume of 234,076 shares, the days-to-cover ratio is currently 0.7 days. Based on an average trading volume of 234,076 shares, the days-to-cover ratio is currently 0.7 days. Approximately 3.0% of the company’s stock are short sold.

Institutional Investors Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Citadel Advisors LLC bought a new stake in Lipocine Inc. (NASDAQ:LPCN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 14,247 shares of the specialty pharmaceutical company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned 0.26% of Lipocine at the end of the most recent reporting period. Institutional investors own 9.11% of the company’s stock.

Lipocine Price Performance

Lipocine stock traded down $0.13 during midday trading on Friday, reaching $11.13. The company’s stock had a trading volume of 244,760 shares, compared to its average volume of 206,857. The stock has a market capitalization of $61.77 million, a P/E ratio of -10.91 and a beta of 0.92. The stock’s 50-day simple moving average is $4.97 and its 200-day simple moving average is $3.69. Lipocine has a 52-week low of $2.52 and a 52-week high of $12.37.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, November 6th. The specialty pharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.03). The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.24 million. Lipocine had a negative net margin of 126.67% and a negative return on equity of 30.65%.

Wall Street Analyst Weigh In

Several research firms have recently commented on LPCN. HC Wainwright reduced their price target on Lipocine from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Lipocine presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.